Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 13/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 13/20 | 0.54 |
| ▸ | PDE4A | P27815 | 6/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | PDE2A | O00408 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10353452 | 0.90 | SMN1; SMN2 (0.81) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL927560 | 0.83 | SMN1; SMN2 (0.70) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL9687996 | 0.83 | SMN1; SMN2 (0.70) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL10556720 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL11035016 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL6331085 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL2846257 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL8302890 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL7273533 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL2798028 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2KCNH2LMNAMAPTNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| CN-101189233-A | Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor | ABBOTT LAB (US) | 2008-05-28 | — | — | CN | disclosed |
| US-7309699-B2 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | JI JIANGUO | 2007-11-29 | — | — | US | disclosed |
| EP-1699785-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1664045-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Abbott Laboratories (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005066166-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | CHRNA7, CHRNA9, CHRNA1 | SMN1; SMN2 1649/4885KCNH2 862/4885LMNA 1775/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | SMN1; SMN2 819/4885KCNH2 340/4885LMNA 1830/4885 |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | CHRNA7, CHRNA9, CHRNA1 | SMN1; SMN2 1649/4885KCNH2 862/4885LMNA 1775/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | SMN1; SMN2 1186/4885KCNH2 765/4885LMNA 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.